During the last session, ImmunityBio Inc (NASDAQ:IBRX)’s traded shares were 9.82 million, with the beta value of the company hitting 0.63. At the end of the trading day, the stock’s price was $3.04, reflecting an intraday loss of -3.49% or -$0.11. The 52-week high for the IBRX share is $10.53, that puts it down -246.38 from that peak though still a striking -0.66% loss since the share price plummeted to a 52-week low of $3.06. The company’s market capitalization is $2.12B, and the average intraday trading volume over the past 10 days was 5.59 million shares, and the average trade volume was 5.56 million shares over the past three months.
ImmunityBio Inc (IBRX) received a consensus recommendation of Sell from analysts. That translates to a mean rating of 1.67. IBRX has a Sell rating from 1 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 0 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
ImmunityBio Inc (NASDAQ:IBRX) trade information
ImmunityBio Inc (IBRX) registered a -3.49% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.49% in intraday trading to $3.04, hitting a weekly high. The stock’s 5-day price performance is -33.48%, and it has moved by -38.59% in 30 days. Based on these gigs, the overall price performance for the year is -18.28%. The short interest in ImmunityBio Inc (NASDAQ:IBRX) is 49.78 million shares and it means that shorts have 9.34 day(s) to cover.
The consensus price target of analysts on Wall Street is $8, which implies an increase of 62.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $8 and $8 respectively. As a result, IBRX is trading at a discount of -163.16% off the target high and -163.16% off the low.
ImmunityBio Inc (IBRX) estimates and forecasts
Statistics show that ImmunityBio Inc has underperformed its competitors in share price, compared to the industry in which it operates. ImmunityBio Inc (IBRX) shares have gone down -48.21% during the last six months, with a year-to-date growth rate less than the industry average at 7.07% against 17.10. In the rating firms’ projections, revenue will increase 3,745.87% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 9.07M as predicted by 1 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 20.02M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 139k and 40k respectively. In this case, analysts expect current quarter sales to grow by 6,425.90% and then jump by 49,962.50% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 1.17%. While earnings are projected to return 27.54% in 2024, the next five years will return -1.70% per annum.
IBRX Dividends
ImmunityBio Inc is due to release its next quarterly earnings in January. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
ImmunityBio Inc (NASDAQ:IBRX)’s Major holders
ImmunityBio Inc insiders own 77.00% of total outstanding shares while institutional holders control 10.11%, with the float percentage being 43.97%. VANGUARD GROUP INC is the largest shareholder of the company, while 255.0 institutions own stock in it. As of 2024-06-30, the company held over 13.83 million shares (or 2.0558% of all shares), a total value of $87.42 million in shares.
The next largest institutional holding, with 11.42 million shares, is of BLACKROCK INC.’s that is approximately 1.6978% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $72.19 million.
